Press release
HER2 Positive Gastric Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight
Explore our latest breakthroughs in HER2 Positive Gastric Cancer Research. Learn more about our innovative pipeline today! @ HER2 Positive Gastric Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HER2 Positive Gastric Cancer Pipeline Report
* June 2024:- Yuhan Corporation - A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors.
* June 2024:- DualityBio Inc. - A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors
* June 2024:- Jazz Pharmaceuticals - A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA).
* June 2024:- Seagen Inc. - This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer.
* June 2024:- Novartis Pharmaceuticals - A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry.
* June 2024:- Astellas Pharma Global Development, Inc. - A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
* DelveInsight's HER2 Positive Gastric Cancer pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for HER2 Positive Gastric Cancer treatment.
* The leading HER2 Positive Gastric Cancer Companies such as Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
* Promising HER2 Positive Gastric Cancer Therapies such as YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
Stay informed about the cutting-edge advancements in HER2 Positive Gastric Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ HER2 Positive Gastric Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer Emerging Drugs
* SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
SHR-A1811 is a novel anti-HER2 antibody-drug conjugate (ADC) that features an optimized molecular design to enhance plasma stability and bystander effect. Hengrui Pharma is currently conducting more than 10 clinical studies of SHR-A1811 from phase 1 to phase 3 to evaluate its safety and efficacy as single agent or combination therapy in a wide variety of cancer indications. Currently, the drug is in Phase III stage of its development for the treatment of HER2-positive Gastric Cancer.
* Cinrebafusp alfa: Pieris Pharmaceuticals
Cinrebafusp alfa (PRS-343) is a 4-1BB/HER2 fusion protein comprising 4-1BB-targeting Anticalin proteins and a HER2-targeting antibody. The drug candidate is currently in phase 2 development for the treatment of HER2-expressing solid tumors. In phase 1 studies, cinrebafusp alfa has shown an acceptable safety profile at all doses tested with no dose-limiting toxicities. The bispecific also showed a dose response and a 4-1BB-driven mechanism of action based on clinical benefit and pharmacodynamic correlates. Currently, the drug is in Phase II stage of its development for the treatment of HER2-positive Gastric Cancer.
* BI-1607: BioInvent International
BI-1607 is an FcRIIB-blocking antibody that differs from BI-1206 (BioInvent's clinical-stage FcRIIB antibody) in that it has been engineered for reduced Fc-binding to FcRs. Preclinical proof-of-concept data indicate that combined treatment with BI-1607 may both enhance efficacy of current anti-HER2 regimens and increase response rates in patients no longer responding to anti-HER2-directed therapies such as trastuzumab. Currently, the drug is in Phase I/II stage of its development for the treatment of HER2-positive Gastric Cancer.
Learn more about HER2 Positive Gastric Cancer Drugs opportunities in our groundbreaking HER2 Positive Gastric Cancer Research and development projects @ HER2 Positive Gastric Cancer Unmet Needs [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
HER2 Positive Gastric Cancer Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Discover the latest advancements in HER2 Positive Gastric Cancer Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ HER2 Positive Gastric Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HER2 Positive Gastric Cancer Companies and Therapies
* BDC-1001: Bolt Therapeutics Inc.
* KN026: Shanghai JMT-Bio Inc.
* YH32367: Yuhan Corporation
* Margetuximab: MacroGenics
* Zanidatamab: Jazz Pharmaceuticals
Scope of the HER2 Positive Gastric Cancer Pipeline Report
* Coverage- Global
* HER2 Positive Gastric Cancer Companies- Jiangsu HengRui Medicine Co., Ltd., Pieris Pharmaceuticals, BioInvent International, Daiichi Sankyo|AstraZeneca, Shanghai JMT-Bio Inc., Acepodia Biotech, Inc., Klus Pharma Inc., Carisma Therapeutics Inc., Novartis Pharmaceuticals, Celularity Incorporated, Hoffmann-La Roche, DualityBio Inc., Shanghai Miracogen Inc.., Bavarian Nordic, and others.
* HER2 Positive Gastric Cancer Therapies- YH32367, BI-1607, Trastuzumab, BDC-1001, Nivolumab, KN026, BNT323, and others.
* HER2 Positive Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HER2 Positive Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HER2 Positive Gastric Cancer Pipeline on our website @ HER2 Positive Gastric Cancer Drugs and Companies [https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* HER2-positive Gastric Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* HER2-positive Gastric Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Cinrebafusp alfa: Pieris Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* BI-1607: BioInvent International
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* HER2-positive Gastric Cancer Key Companies
* HER2-positive Gastric Cancer Key Products
* HER2-positive Gastric Cancer- Unmet Needs
* HER2-positive Gastric Cancer- Market Drivers and Barriers
* HER2-positive Gastric Cancer- Future Perspectives and Conclusion
* HER2-positive Gastric Cancer Analyst Views
* HER2-positive Gastric Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=her2-positive-gastric-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2 Positive Gastric Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here
News-ID: 3551877 • Views: …
More Releases from ABNewswire
Freelance Platforms Market Forecast to Reach USD 16.54 Billion by 2030, Driven b …
Mordor Intelligence has published a new report on the Freelance Platforms Market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Freelance Platforms Market Outlook
The freelance platforms market size [https://www.mordorintelligence.com/industry-reports/freelance-platforms-market?utm_source=abnewswire] stands at USD 7.65 billion in 2025 and is forecast to reach USD 16.54 billion by 2030, advancing at a 16.66% CAGR. The Freelance Platforms Market share is currently dominated by platform models, while services are gaining momentum with…
Surprising Comparison: Disney vs. Taylor Swift Concert Costs
Disney World Ticket Prices Nearly Double Over Past Decade: PixieVacations Reveals Comprehensive Analysis and Money-Saving Strategies for 2025 Travelers
Walt Disney World ticket prices reach historic highs in 2025, with peak one-day Magic Kingdom tickets now exceeding $200 for the first time ever, PixieVacations.com has released a comprehensive analysis of Disney World ticket prices over the past decade. The leading Disney vacation planning service aims to help families navigate these rising…
Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
Skin cancer is rarely viewed as life-changing, but for millions of patients each year, basal cell carcinoma brings a cycle of surgeries, scars, and slow recovery that feels endless. Hospitals are overloaded, dermatologists are booked months in advance, and treatments that remove tumors often leave lasting damage. The challenge is not identifying the cancer; it is finding a way to treat it without cutting the patient open. That is the…
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation.
Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
